Objective: Concern about coronavirus 2019 (COVID-19) morbidity and mortality has drawn attention to the potential role of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) because the SARS-CoV-2 uses the ACE2 receptor as its point of entry into the body. Our objective is to explore what is known and unknown about the role of ACE inhibitors and ARBs in COVID-19 patients. It is not clear if and to what degree the SARS-CoV-2 virus affects the renin-angoiotensin system. Early studies from China which speculated on the role of ACE inhibition and ARBs did not evaluate the drug regimens. A vast body of evidence supports the use of ACE inhibitors and ARBs in hypertensive patients and patients with heart failure, and very little evidence has been acquired about their role in COVID-19. Conclusion: There is good evidence in support of the use of ACE inhibitors and ARBs in indicated patients with hypertension and heart failure, and clinicians should be reticent about abruptly withdrawing these drugs based on a paucity of evidence.
|Titolo:||The concern about ACE/ARB and COVID-19: Time to hold your horses!|
PALADINI, ANTONELLA [Writing – Review & Editing]
|Data di pubblicazione:||2020|
|Appare nelle tipologie:||1.1 Articolo in rivista|